Identifying uncertainties about the effects of treatments for schizophrenia

Journal of Mental Health

Volumn 15, Issue 3, 2006, Pages 263-268

  Lloyd, Keith ^a   Rose, Diana ^b   Fenton, Mark ^c  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c James Lind Alliance   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

AGGRESSION; AMNESIA; CEREBROVASCULAR ACCIDENT; DEATH; EDITORIAL; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; HUMAN; PRACTICE GUIDELINE; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOMATOLOGY;

EID: 33745698751     PISSN: 09638237     EISSN: 13600567     Source Type: Journal    
DOI: 10.1080/09638230600731586     Document Type: Editorial

References (17)

1. Alexander, J., Tharyan, P., Adams, C., John, T., Mol, C., & Philip, J. (2004). Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine. British Journal of Psychiatry, 185, 63-69.
2. Ballard, C., & Waite, J. (2006). The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Systematic Reviews, 1, CD003476.
3. Belgamwar, R. B., & Fenton, M. (2005). Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Systematic Reviews, 2, CD003729.
4. Chalmers, I. (2004). Well informed uncertainties about the effects of treatments: How should clinicians and patients respond? British Medical Journal, 328, 475-476.
5. Clark, M., & Chilvers, C. (2005). Mental health research system in England: Yesterday, today and tomorrow. Psychiatric Bulletin, 29, 441-445.
6. CRASH group (2004). Effect of intravenous corticosteroids on death within 14 days in 10,008 adults with clinically significant head injury (MRC CRASH Trial), randomized, placebo-controlled trial. Lancet, 364, 1321-1328.
7. Department of Health (2004). Research for Patient Benefit Working Party - Final Report. London: Department of Health. Gateway reference number: 3277.
8. Department of Health (2006). Best Research for Best Health - a new national health research strategy. London: Department of Health. Gateway reference number: 6050.
9. Fink, M., Shaw, R., Gross, G., et al. (1958). Comparative study of chlorpromazine and insulin coma in therapy of psychosis. Journal of the American Medical Association, 166, 1846-1850.
10. Gibson, R. C., Fenton, M., Coutinho, E. S., & Campbell, C. (2004). Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database of Systematic Reviews, 3, CD000525.
11. Lelliott, P. (2005). Beware the problems of centralisation. Commentary on "Mental health research systems in England". Psychiatric Bulletin, 29, 446-447.
12. Mental Health Research Funders' Group (2005). Strategic Analysis of UK Mental Health Research Funding. Downloadable from http://www.mrc.ac.uk/pdf- mhrfg_strategic_analysis_report_final.pdf
13. Milner, K. K., & Valenstein, M. (2002). A comparison of guidelines for the treatment of schizophrenia. Psychiatric Services, 53, 888-890.
14. Rose, D., Fleischmann, P., & Wykes, T. (2004). Consumers' perspectives on ECT: A qualitative analysis. Journal of Mental Health, 13, 285-294.
15. Sargant, W., & Slater, E. (1944). An introduction to physical methods of treatment in psychiatry, 1st edn. Edinburgh: E & S Livingstone.
16. Szmuckler, G. (2005). The ground is in great shape, but can we field a kitted-out team? Psychiatric Bulletin, 29, 447-448.
17. Thornicroft, G., Rose, D., Huxley, P., Dale, G., & Wykes, T. (2002). What are the research priorities of mental health service users? Editorial. Journal of Mental Health, 11, 1-5.